Trials / Conditions / Fallopian Tube Adenocarcinoma

Fallopian Tube Adenocarcinoma

10 registered clinical trials studyying Fallopian Tube Adenocarcinoma.

Status	Trial	Sponsor	Phase
Completed	FT516 and IL2 With Enoblituzumab for Ovarian Cancer NCT04630769	Masonic Cancer Center, University of Minnesota	Phase 1
Active Not Recruiting	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal De NCT04498117	CanariaBio Inc.	Phase 3
Terminated	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors NCT03641287	University of Washington	N/A
Terminated	Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mes NCT03608618	MaxCyte, Inc.	Phase 1
Completed	Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of M NCT03593681	Boston Scientific Corporation	—
Terminated	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, F NCT02923739	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013	National Cancer Institute (NCI)	Phase 2
Completed	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707	Mayo Clinic	Phase 1
Completed	Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresect NCT02217956	Gustave Roussy, Cancer Campus, Grand Paris	Phase 1
Terminated	YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal NCT00899093	Gynecologic Oncology Group	—